Hospital Infection Therapeutics Market to Reach US$3.6 bn by 2020, Owing to Globally Rising Healthcare Awareness: Transparency Market Research

ALBANY, New York, February 1, 2016 /PRNewswire/ --

A new Transparency Market Research report states that the global hospital infection therapeutics market stood at US$3.0 bn in 2013 and is predicted to reach US$3.6 bn by 2020. It is expected to expand at a CAGR of 3.10% from 2014 to 2020. The title of the report is "Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020".

As per the report, the prime factors stimulating the growth of the market for hospital infection therapeutics include the rising prevalence of numerous infections acquired in hospitals, growing aging population, increasing demand for enhanced therapeutic drugs, and rising healthcare awareness. The areas highly prone to hospital-acquired infections include humid and hot areas in medium-to-low-income countries suffering from an absence of standard healthcare amenities. On the other hand, rising surveillance programs and rising control of numerous infections may hamper the growth of the market in the coming years.

Browse Research Report on Hospital Infection Therapeutics Market at http://www.transparencymarketresearch.com/hospital-infection-therapeutics.html

The patients undergoing treatments in hospitals can develop infections in the course of their stay in the hospitals. These infections are called as hospital infections or hospital-acquired infections (HAI). These infections spread in healthcare environments such as outpatient surgery centers, rehabilitation centers, dialysis centers, hospitals, and nursing homes.

On the basis of drug type, the hospital infection therapeutics market is segmented into antiviral drugs, antibacterial drugs, and antifungal drugs. Amongst these, the segment of antibacterial drugs held the biggest share of 70.7% within the global hospital infection therapeutics market. This segment is also predicted to be the most swiftly developing segment in the forecast period between 2014 and 2020.

On the basis of the type of infection, the market is segmented into surgical site infections, hospital-acquired pneumonia, urinary tract infections, bloodstream infections, gastrointestinal disorders, and other hospital infections. Amongst these, the segment of hospital-acquired pneumonia led the market in 2013 and represented a share of more than 20% in the market. On the other hand, the segment of urinary tract infections is the most swiftly developing segment in the forecast horizon.

Avail a Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1280

On the basis of geography, the market is segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). Amongst these, in 2013, North America led the global hospital infection therapeutics market and was trailed by the Europe market. The major factors fuelling the Europe hospital-acquired therapeutics market include the increasing prevalence of numerous hospital infections, rising demand for improved therapeutics, and the increasing count of multidrug-resistant microbial pathogens, among others. In addition, this region has a huge aging population base and this population is more prone to various hospital-acquired infections owing to their low immunity levels, thus requiring usage of numerous antimicrobial therapeutics, thus boosting the growth of the hospital infection therapeutics market. On the other hand, Asia Pacific is the most swiftly developing regional segment of the market owing to rising prevalence of hospital-acquired infections in the area.

Key Players: 

According to the report, the prominent players operating in the market include AstraZeneca plc. Actavis plc, Bayer AG, Cubist Pharmaceuticals, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson Services, Inc., Sanofi, and Pfizer, Inc., among others.

Browse Regional Analysis: http://www.europlat.org/rapidly-increasing-multi-drug-resistance-and-rising-number-of-hospital-infected-patients-a-massive-threat-to-hospitals-other-healthcare-institutions.htm

The hospital infection therapeutics market is segmented as follows: 

Hospital Infection Therapeutics Market, by Drug Type 

• Antibacterial Drugs
• Antiviral Drugs
• Antifungal Drugs

Hospital Infection Therapeutics Market, by Major Infections 

• Hospital-Acquired Pneumonia
• Surgical Site Infections
• Urinary Tract Infections
• Gastrointestinal Disorders
• Bloodstream Infections
• Other Hospital Infections

Hospital Infection Therapeutics Market, by Geography 

• North America
• Europe
• Asia Pacific
• Rest of the World (RoW) 

Trending Reports by Transparency Market Research:  

• Inhalation and Nasal Spray Generic Drugs Market:  

http://www.transparencymarketresearch.com/inhalation-nasal-spray-generic-drugs.html

• LATAM Adalimumab Market:  

http://www.transparencymarketresearch.com/latam-adalimumab-market.html

About Us:  

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact:
Mr. Sudip.S
90 State Street, Suite 700
Albany, NY 12207
United States.
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com